UlinastatinAlternative Names: Miraclid; MR-20V
Latest Information Update: 17 Feb 2010
At a glance
- Originator Mochida Pharmaceutical
- Class Anti-inflammatories; Cytoprotectives; Glycoproteins; Uroprotectives
- Mechanism of Action Enzyme inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pancreatitis; Vascular disorders
- Suspended Preterm labour
Most Recent Events
- 15 Mar 2016 Biomarkers information updated